| http://dbpedia.org/ontology/abstract
|
MOR103 (également connu sous le nom de GSK … MOR103 (également connu sous le nom de GSK3196165) est un anticorps entièrement humain qui a été développé par la société de biotechnologie MorphoSys. Il peut également être désigné sous le nom d'anticorps HuCAL, HuCAL signifiant « Human Combinatorial Antibody Library » et étant une technologie utilisée pour générer des anticorps monoclonaux. MOR103 est dirigé contre le facteur de stimulation des colonies de granulocytes-macrophages (FSC-GM), une glycoprotéine monomérique fonctionnant comme une cytokine favorisant à la fois la prolifération et l'activation des macrophages et des granulocytes neutrophiles.rophages et des granulocytes neutrophiles.
, Otilimab (development codes MOR103 and GSK … Otilimab (development codes MOR103 and GSK3196165) is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.activation of macrophages and neutrophils.
|
| http://dbpedia.org/ontology/casNumber
|
1638332-55-4
|
| http://dbpedia.org/ontology/fdaUniiCode
|
Y8127R3VCH
|
| http://dbpedia.org/ontology/kegg
|
D11343
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Antibody.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
57748667
|
| http://dbpedia.org/ontology/wikiPageLength
|
7906
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1053699259
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Tumor_necrosis_factor_alpha +
, http://dbpedia.org/resource/Cytokine +
, http://dbpedia.org/resource/Immunogenicity +
, http://dbpedia.org/resource/Adalimumab +
, http://dbpedia.org/resource/T_helper_cell +
, http://dbpedia.org/resource/Neutrophil +
, http://dbpedia.org/resource/Inflammation +
, http://dbpedia.org/resource/T_cell +
, http://dbpedia.org/resource/Granulocyte-macrophage_colony-stimulating_factor +
, http://dbpedia.org/resource/Protease +
, http://dbpedia.org/resource/Antibody +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/T_helper_17_cell +
, http://dbpedia.org/resource/Macrophage +
, http://dbpedia.org/resource/Immunotherapy +
, http://dbpedia.org/resource/Central_nervous_system +
, http://dbpedia.org/resource/Alemtuzumab +
, http://dbpedia.org/resource/Hepatitis_B +
, http://dbpedia.org/resource/Multiple_sclerosis +
, http://dbpedia.org/resource/Category:Arthritis +
, http://dbpedia.org/resource/MHC_class_II +
, http://dbpedia.org/resource/Relapsing_remitting_multiple_sclerosis +
, http://dbpedia.org/resource/Tuberculosis +
, http://dbpedia.org/resource/Matrix_metalloproteinase +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Drug_tolerance +
, http://dbpedia.org/resource/Natalizumab +
, http://dbpedia.org/resource/Th1_cell +
, http://dbpedia.org/resource/Hydrogen_peroxide +
, http://dbpedia.org/resource/Blood%E2%80%93brain_barrier +
, http://dbpedia.org/resource/Osteoarthritis +
, http://dbpedia.org/resource/Rheumatoid_arthritis +
, http://dbpedia.org/resource/Daclizumab +
, http://dbpedia.org/resource/Ocrelizumab +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Chemokine +
, http://dbpedia.org/resource/File:Antibody.svg +
, http://dbpedia.org/resource/Infliximab +
, http://dbpedia.org/resource/Autoimmune_disease +
, http://dbpedia.org/resource/Chemotaxis +
, http://dbpedia.org/resource/MorphoSys +
, http://dbpedia.org/resource/Monoclonal_antibody_therapy +
, http://dbpedia.org/resource/B_cell +
|
| http://dbpedia.org/property/casNumber
|
1638332
|
| http://dbpedia.org/property/kegg
|
D11343
|
| http://dbpedia.org/property/legalStatus
|
Investigational
|
| http://dbpedia.org/property/synonyms
|
GSK3196165; MOR103
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
Y8127R3VCH
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Upe +
, http://dbpedia.org/resource/Template:Infobox_drug +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Category:Arthritis +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Otilimab?oldid=1053699259&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Antibody.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Otilimab +
|
| owl:sameAs |
http://fr.dbpedia.org/resource/MOR103 +
, http://www.wikidata.org/entity/Q56291893 +
, https://global.dbpedia.org/id/5E31w +
, http://dbpedia.org/resource/Otilimab +
|
| rdf:type |
http://www.wikidata.org/entity/Q8386 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/Drug +
|
| rdfs:comment |
MOR103 (également connu sous le nom de GSK … MOR103 (également connu sous le nom de GSK3196165) est un anticorps entièrement humain qui a été développé par la société de biotechnologie MorphoSys. Il peut également être désigné sous le nom d'anticorps HuCAL, HuCAL signifiant « Human Combinatorial Antibody Library » et étant une technologie utilisée pour générer des anticorps monoclonaux. MOR103 est dirigé contre le facteur de stimulation des colonies de granulocytes-macrophages (FSC-GM), une glycoprotéine monomérique fonctionnant comme une cytokine favorisant à la fois la prolifération et l'activation des macrophages et des granulocytes neutrophiles.rophages et des granulocytes neutrophiles.
, Otilimab (development codes MOR103 and GSK … Otilimab (development codes MOR103 and GSK3196165) is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.activation of macrophages and neutrophils.
|
| rdfs:label |
Otilimab
, MOR103
|
